(INNS)
TRASTUZUMAB REZETECAN(INND)
TRASTUZUMAB REZETEKAN(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)], HUMANIZED MONOCLONAL ANTIBODY, CONJUGATED VIA A CLEAVABLE LINKER WITH A CAMPTOTHECIN DERIVATIVE; GAMMA1 HEAVY CHAIN HUMANIZED (1-450) [VH (HOMO SAPIENS IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1 (CH1 R120>K (217) (121- 218), HINGE 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-214') [V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')]; ... PROPOSED INN: LIST 127, RECOMMENDED LIST: 89(WHO)
TRASTUZUMABUM REZETECANUM(INN)